#her2low
LightNews LightNews
dunnedeirdre.bsky.social
Check out this new study published in ESMO Open looking at clinical outcomes of early stage #TripleNegativeBreastCancer after neoadjuvant chemotherapy according to #HER2low status☆
www.sciencedirect.com/science/arti...
@ptarantinomd.bsky.social
November 18, 2024 at 9:33 PM
gizemyv.bsky.social
Happy to share our perspective article about HER2low subtype and endocrine therapy resistance is online! www.frontiersin.org/journals/onc...
Frontiers | The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways
www.frontiersin.org
November 22, 2024 at 2:12 PM
combinedstrategies.bsky.social
Immunohistochemistry v. Genomic Profiling: Game on for Her2Low. #her2low #genomictesting
Current breast cancer classification methods, particularly immunohistochemistry and PAM50, face challenges in accurately characterizing the HER2-low subtype, ... read more:
www.nature.com/articles/s41...
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype - npj Breast Cancer
npj Breast Cancer - The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype
www.nature.com
February 21, 2025 at 1:41 AM
chornukopia.bsky.social
We aren't just statistics. We are mothers, daughters, and friends. We are out of time, and we are demanding change from AstraZeneca Wes Streeting @nhsengland @DaiichiSankyoUK
#metupuk #breastcancernow #Enhertu #enhertunow #her2low

🧵1/2
April 3, 2026 at 11:16 AM
renshaw01.bsky.social
Forwarding for METUPUK from X/Twitter

METUPUK is the ONLY metastatic breast cancer patient advocacy group in the UK. They are here to push and promote issues with secondary/metastatic breast cancer. Metastatic breast cancer is currently incurable.
Enhertu emergency. METUPUK is incredibly disappointed with the decision to NOT recommend Enhertu in England for HER2Low patients. We want to see NICE and the NHS back to the negotiating table with the drug companies but time is short. Please sign and share widely the petition urgently.
October 20, 2024 at 3:27 PM
theoncologynetwork.bsky.social
🚨 New Podcast 🚨

Dive into the evolving world of HER2-low expression in metastatic breast cancer.

🎙️ Join Prof. Fran Boyle & Dr. Sanjeev Kumar to unpack HER2 testing, patient comms & emerging therapies

🔗 Listen now: t.ly/jFmny #MedSky #OncSky #CanSky #OncologyPodcast #BreastCancer #HER2Low #HER2
March 7, 2025 at 2:59 AM
schnrpsl.bsky.social
Bei meiner Therapeutin lagen medizinische Zeitungen rum, hab mir eine geschnappt, ich glaube das ist tatsächlich nur für Mediziner:innen, das ist ja wie eine Fremdsprache :'D Wow!
PFS-Vorteil bestätigte sich in betrachteten Subgruppen Die Studie hatte ihren primären Endpunkt erreicht. T-DXd verlän-gerte das progressionsfreie Überle-ben für die HER2low-Patient:innen (n=713/866) hoch signifikant (medianes PFS: 13,2 Monate vs. 8,1 Monate; HR 0,62; p <0,0001). Das PFS-Ergebnis bestätigte sich für die Gesamtpopulation (sekundärer Endpunkt; HR 0,64; p <0,0001). Die aktuellen Subgruppenana-lysen unterstreichen die Wirksam-keitsvorteile von T-DXd unabhängig davon, wie lange Erkrankte auf die vorangegangene endokrinbasierte Erstlinientherapie (plus CDK4/6-Inhibitor) angesprochen hatten (<6 Monate: HR 0,38; 6-12 Monate: HR 0,69; > 12 Monate: HR 0,67) aus Isatuximab, Lenalidomid, Bortezomib und De-xamethason (Isa-RVd) bei für eine Transplantation nicht geeigneten Ex-krankten mit neu diagnostiziertem Multiplem Myelom (NDMM). Vor der FDA ist die Kombination in die-ser Indikation bereits zugelassen. Auch in der GMMG-HD7-Studio steht die Substanz auf dem Prüf-stand. In Teil 1 erhielten 662 Teil-nehmende mit NDMM 1:1 ran-domisiert Isa-RVd oder RVd zur Induktion für insgesamt 18 Wochen, gefolgt von einer Hochdosischemo-therapie und autologen Stammzell-transplantation (ASCT). Sprachen die Betroffenen nicht komplett an oder hatten sie eine Hochrisikoer-krankung, konnten sie im Anschluss eine Tandem-Transplantation be-kommen. Teil 2 besteht aus
March 3, 2025 at 6:35 PM
breastcancerstoday.bsky.social
A new HER2-low scoring system could help pathologists more accurately identify HER2-low metastatic breast cancer—potentially expanding patient access to HER2-targeted therapies.
🔗 www.docwirenews.com/post/improvi...
#BreastCancer #HER2low #CancerDiagnostics #OncTwitter @petermaccc.bsky.social
Improving HER2-Low Diagnosis in Metastatic Breast Cancer: Scoring System Enhances Precision | Docwire News
A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.
www.docwirenews.com
April 17, 2025 at 4:02 PM
oncoalert.bsky.social
Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence

link.springer.com/article/10.1...
August 8, 2025 at 10:01 AM
stage4kelly.bsky.social
RC48-ADC (sounds like something from Star Wars, maybe R2D2's cousin?) has shown efficacy in HER2low as well as HER2+ (abstract 1022 Wang et al). Trial is open in China, global trial may be on the way. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
stage4kelly.bsky.social
The idea of HER2low may also apply to those with TNBC, again opening up new treatment options with HER2 directed ADCs (antibody to HER2 coupled with a cancer cell killing agent. Abstract e13046 Yang et al showed 38% of #metastatic TNBC was HER2low. #ASCO21 #bcsm
November 18, 2024 at 1:36 AM
stage4kelly.bsky.social
Abstract 1052 Bao et al showed that those with HER2low ER+ MBC had a shorter PFS on endocrine therapy + CDK 4/6 inhibitor, compared to those with HER2=0 on IHC. #ASCO21 #bcsm #HER2low
November 18, 2024 at 1:08 AM
stage4kelly.bsky.social
Interesting area for those of us w/ ER+HER2- #metastaticbreastcancer is the idea of HER2low (1-2+ on IHC), which could open up some exciting drugs recently approved for HER2+ disease, like trastuzumab deruxtecan (enhertu), to us. We also need predictive biomarkers. #ASCO21 #bcsm
November 18, 2024 at 12:38 AM
stage4kelly.bsky.social
trastuumab deruxtecan (enhertu) looks like ti may be effective in HER2low MBC as well. #bcsm
November 17, 2024 at 10:04 PM
stage4kelly.bsky.social
But like everything else, there are side effects, mainly interstitial lung disease (aka one monitors or inflammation of the lungs). Nause can be pretty bad too, right @swaggsheila1? #HER2low #SABCS22 #bcsm
November 17, 2024 at 11:25 AM
stage4kelly.bsky.social
And why should we care? Because a ton of people who are classified as HER2- have 1+ or 2+ expression and could benefit from TDxD and maybe other HER2 targeted therapies. #HER2low #SABCS22 #bcsm
November 17, 2024 at 11:06 AM
stage4kelly.bsky.social
First event (for me) at #SABCS22 is @abreastcancer/NBCC joint session on #HER2low where the last Kate Petrides was honored with a moment of silence. I think Kate would have preferred a moment of action. @metavivor #bcsm
November 17, 2024 at 10:44 AM
stage4kelly.bsky.social
Starting off with THE hot topic: #HER2low. First, review of what HER2 overexpression means and what ADCs (anitibody-drug conjugates) do. DESTINY breast04 showed this can work even with low expression of HER2 (all BC cells have some HER2 receptors). #bcsm
November 17, 2024 at 10:44 AM
stage4kelly.bsky.social
How low can we go in HER2low? Can more than 0 but less than 1+ on IHC still respond to TDXd? We’ll see #ESMOBreast23
November 17, 2024 at 5:17 AM
stage4kelly.bsky.social
TDXd (enhertu) showed efficacy in almost every ER+ subgroup and pretty darn impressive in HER2low mTNBC (sorry, glitchy conference app and missed the slide) #ESMOBreast2023
November 17, 2024 at 4:54 AM
stage4kelly.bsky.social
First up TDXd aka Enhertu, a ADC approved for both HER2+ and HER2low MBC. Pretty sure it was approved in HER2low population about a year ago due to results from DESTINY-breast02 trial. #SABCS23
November 17, 2024 at 2:10 AM
itstuff.bsky.social
www.mskcc.org/news/new-dru...

ENROLL ALL BREAST CANCER PATIENTS INTO THIS, AND LOOK FOR HER2LOW EXPERTS IN CASE CANCERS CHANGE PROGNOSTIC STATUSES :
FDA Approves New Drug Combination for ER+, HER2- Breast Cancer
Learn how a three-drug treatment appears to be very effective for ER+, HER2- breast cancers.
www.mskcc.org
February 14, 2025 at 2:48 AM
breastcancerstoday.bsky.social
Dr Sara Nunnery breaks down the evolving HER2 classification system and the clinical impact of DESTINY-Breast06. Hear how #Enhertu is reshaping treatment for HR+/HER2-low #BreastCancer. Watch now ⬇️ docwirenews.com/post/reclass... #HER2Low #DESTINYBreast06 #Oncology #CancerResearch
Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer | Docwire News
Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
docwirenews.com
April 22, 2025 at 9:02 PM